The estimated Net Worth of Veena Singh is at least $11.6 Tausend dollars as of 19 October 2016. Dr Singh owns over 10,000 units of Biocept Inc stock worth over $11,597 and over the last 10 years he sold BIOC stock worth over $0.
Dr has made over 2 trades of the Biocept Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of BIOC stock worth $11,000 on 19 October 2016.
The largest trade he's ever made was buying 10,000 units of Biocept Inc stock on 19 October 2016 worth over $11,000. On average, Dr trades about 1,875 units every 64 days since 2014. As of 19 October 2016 he still owns at least 26,666 units of Biocept Inc stock.
You can see the complete history of Dr Singh stock trades at the bottom of the page.
Dr. Veena M. Singh is the Sr. Medical Director at Biocept Inc.
Dr Singh is 46, he's been the Sr. Medical Director of Biocept Inc since . There are 18 older and no younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.
Veena's mailing address filed with the SEC is 5810 NANCY RIDGE DRIVE, STE 150, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff und David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Biocept Inc executives and other stock owners filed with the SEC include: